Pharmacokinetics of moxifloxacin in an infant with Mycoplasma hominis meningitis

Pediatr Infect Dis J. 2012 Feb;31(2):197-9. doi: 10.1097/INF.0b013e31823980c3.

Abstract

Treatment of Mycoplasma hominis meningitis in infants is limited by a lack of consensus regarding therapy and limited pharmacokinetic data for agents to which M. hominis is susceptible. We report the successful treatment of a premature infant suffering from M. hominis meningitis with doxycycline and moxifloxacin and provide a pharmacokinetic profile of moxifloxacin.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / pharmacokinetics*
  • Aza Compounds / administration & dosage
  • Aza Compounds / pharmacokinetics*
  • Child
  • Child, Preschool
  • Doxycycline / administration & dosage
  • Female
  • Fluoroquinolones
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Meningitis, Bacterial / drug therapy*
  • Meningitis, Bacterial / microbiology
  • Moxifloxacin
  • Mycoplasma Infections / drug therapy*
  • Mycoplasma Infections / microbiology
  • Mycoplasma hominis / isolation & purification*
  • Pregnancy
  • Quinolines / administration & dosage
  • Quinolines / pharmacokinetics*
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Aza Compounds
  • Fluoroquinolones
  • Quinolines
  • Doxycycline
  • Moxifloxacin